1147639185
Audio Journal of Oncology Podcast

Advertise on podcast: Audio Journal of Oncology Podcast

Categories
Country
United States
This podcast has
101 episodes
Language
English
Explicit
No
Date created
2016/08/25
Latest episode
2026/11/12
Average duration
11 min.
Release period
4 days

Description

As the leading authoritative, peer-reviewed audio source of oncology clinical news for clinicians and healthcare professionals, the AJO Podcast regularly brings you exclusive interviews with the world's leading researchers and clinicians responsible for pushing out the boundaries of science and practice. Medicine, screening, radiotherapy, surgery, clinical trials, cancer care, epidemiology and prevention are covered impartially to give busy cancer professionals access to conversational spoken comments on the clinical implications of cancer developments in the real-world context, as practiced by cancer doctors and clinicians around the globe. The AJO Podcast originates from the Audio Journal of Oncology staffed by ex-BBC professional journalists, and mentored by world-leading cancer practitioners from bodies including the American Society of Clinical Oncology, Cancer Research UK, Istituto Nazionale dei Tumori, and Action Radiotherapy. Each podcast is produced to the highest standards of audio recording and journalism and is subject to editorial appraisal to maintain that content, balance and clinical relevance of news and comment are delivered in a manner that's easy and enjoyable for listening while travelling, taking exercise, working or just relaxing. Please contact Audio Medica with your comments and make your contribution to supporting a vibrant community of clinical cancer communicators!

Unlock Audio Journal of Oncology Podcast podcast Email contact info,
Listeners & Audience details

Email contact information

Direct podcast contact details

Listeners

Audience numbers & engagement insights

Audience details

Podcast Insights

Podcast episodes

Check latest episodes from Audio Journal of Oncology Podcast podcast


Jacob Sands MD; ESMO 2026: Tarlatamab Bispecific Antibody Maintenance Therapy Prolongs Life for Patients with Extensive Stage Small Cell Lung Cancer
2026/11/12
MADRID, Spain—Patients with extensive stage small cell lung cancer now have the green-light to add treatment with the bispecific antibody tarlatamab to their maintenance anti-PD-1 immunotherapy after first line chemo-immunotherapy induction. Results from the phase 3 DeLLphi-305 trial were reported at the 2026 Annual Congress of the European Society for Medical Oncology showing significantly improved overall and progression-free survival. Peter Goodwin spoke with study author Jacob Sands MD, Associate Chief of the Lowe Center for Thoracic Oncology at the Dana-Farber Cancer Institute, in Boston, USA, and Assistant Professor of Medicine at Harvard Medical School:
Mitchell E Fane PhD; AACR 2026: Gamma Delta T-Cell Modulation: a Potential New Component of Immunotherapy for Patients with Metastatic Cutaneous Melanoma?
2026/11/10
SAN DIEGO, USA—The importance of gamma delta T-cells in the progression of cutaneous metastatic melanoma was highlighted at the 2026 Annual Meeting of the American Association for Cancer Research. Epidemiological evidence of a relationship between these very specialized cells and the age-dependency of cancer progression has now been linked to powerful laboratory-based in-vivo studies suggesting a potential role of gamma delta T-cells as components of cancer immunotherapy. Peter Goodwin talked with first author of the research, Mitchell E Fane, Assistant Professor at the Fox Chase Cancer Center’s Cancer Signaling and Microenvironment Program in Philadelphia, USA:
Kai-Keen Shiu PhD FRCP; CSCO 2026: Immune-Resistant Colorectal Cancer: Making Microsatellite Stable Tumors Immunogenic, Circulating Tumor DNA, Neoadjuvant Immunotherapy
2026/11/06
JINAN, China—Biomarker targeting, neoadjuvant immunotherapy and liquid biopsies are among a range of factors promising to make immune-resistant colorectal cancers (such as those with microsatellite stable disease) immunogenic, according to speakers at the Chinese Society of Clinical Oncology 2026 Annual Meeting. Peter Goodwin talked with one of the lead session speakers: Kai-Keen Shiu PhD FRCP, Consultant Gastrointestinal Medical Oncologist at University College London Hospital and Associate Professor at the UCL Cancer Institute in London, UK.
Rebecca Dent MD; ESMO 2026: Dato-DXd Brings Dramatic CNS Responses to Patients with Brain Metastases from Resected Inoperable or Metastatic Triple Negative Breast Cancer
2026/11/05
MADRID, Spain—The antibody-drug conjugate datopotamab deruxtecan (aTrop-2-directed antibody carrying a topoisomerase inhibitor payload) achieved clinically meaningful intracranial responses among patients with resected inoperable or metastatic triple negative breast cancer with CNS involvement in the TROPION-Breast02 study discussed at the 2026 Annual Meeting of the European Society for Medical Oncology. Peter Goodwin heard the details from the study’s first author: Rebecca Dent MD, Senior Consultant Medical Oncologist and Deputy Chief Executive Officer at the National Cancer Centre in Singapore.
James Larkin PhD FRCP F Med Sci, ESMO 2026: Personalized mRNA Cancer Vaccines: Melanoma Study Success Provides Proof of Principle for Other Malignancies
2026/11/02
MADRID, Spain— Personalized mRNA cancer vaccines for a range of tumor types are now seen as a realistic possibility thanks to mRNA technology already harnessed for treating melanoma in the phase III INTerpath-001 trial reported at the 2026 Annual Congress of the European Society for Medical Oncology. Peter Goodwin heard the latest on the potential of cancer vaccines from Scientific Co-Chair of ESMO 2026, James Larkin PhD FRCP F Med Sci, Head of The Royal Marsden Skin Unit, and Joint Training Programme Director for Medical Oncology and Lead of the Cancer Immunotherapy Theme at The Royal Marsden’s Institute of Cancer Research NIHR Biomedical Research Centre, in London UK.
Georgina V Long PhD FRACP; ESMO 2026: Neoantigen mRNA Vaccine Significantly Delays Recurrence in Patients with Resected Melanoma
2026/10/30
MADRID, Spain—Individualized vaccination as adjuvant therapy for patients with stage two to four resected melanoma has achieved positive and highly encouraging outcomes according to findings from the INTerpath-001: Phase 3 study reported at the European Society for Medical Oncology 2026 congress. Patients in the study were randomized to treatment with the mRNA-based neoantigen therapy intismeran autogene added to standard immune checkpoint inhibitor adjuvant therapy, and compared with a control arm of patients receiving checkpoint inhibition alone.
James L Reading PhD; Nature 2026: Regulatory T-Cell Axis Identifies Pre-Malignant Lung Cancer
2026/10/20
LONDON, United Kingdom—Researchers in London have identified patterns of regulatory T-cells that give early warning of high risk for lung cancer. The journal Nature has just published research showing that lung cancer could be intercepted through blood tests years ahead of current screening and diagnostics, and treated with safe targeted drugs some of which are already under investigation. Peter Goodwin called into the Pre-cancer Immunology Laboratory at University College London to hear from the senior author of this research, James Reading PhD.
Joseph Mikhael MD; IMS 2026: Bringing BCMA Therapies to All Patients with Multiple Myeloma at First Relapse
2026/10/19
GLASGOW, Scotland—Joseph Mikhael MD, Professor at the Translational Genomics Research Institute (TGen), Phoenix, Arizona USA, talks with Sarah Maxwell at the International Myeloma Society 2026 Annual Meeting about the importance of introducing B-cell maturation antigen-targeted therapies at first relapse for patients with multiple myeloma.
David R Spigel MD; ASCO 2026: Bispecific PD-1/VEGF Antibody Ivonescimab Extends Life in Patients with Untreated Advanced Non–Small Cell Lung Cancer: Phase 3 HARMONi-6 trial
2026/10/15
CHICAGO, USA—The bispecific antibody ivonescimab (that targets the PD-1 and VEGF molecules) has extended overall survival in patients with untreated advanced squamous non-small cell lung cancer in the latest data from the HARMONi-6 trial reported at the 2026 Annual Meeting of the American Society of Clinical Oncology by Chen Zhiwei from Jiao Tong University in Shanghai, China. Peter Goodwin discusses the findings with ASCO expert David R Spigel MD, President & Chief Medical Officer at the Sarah Cannon Research Institute in Nashville, Tennessee, USA
Zachary Avigan MD; IMS 2026: Predicting Multiple Myeloma Cure: Ultra-Low-Risk Patients Who Have Favorable Outcomes and Can Stop Therapy
2026/10/12
GLASGOW, Scotland—Patients who achieved sustained measurable residual disease negativity for more than 24 months had significantly improved survival outcomes and could be categorized as cured. This isthe implication of findings from a retrospective analysis looking at predicting cure in myeloma reported at the International Myeloma Society 2026 Annual Meeting. Sarah Maxwell heard the details from study author Zachary Avigan MD, Assistant Professor of Medicine in the Division of Hematology and Medical Oncology at Icahn School of Medicine in Mount Sinai Hospital, New York City, USA.
Thomas E. Stinchcombe MD; CSCO 2026: The Journal of Clinical Oncology’s Mission and Vision Going Forwards: New Editor's Global Perspective
2026/10/06
JINAN, China—January 2027 sees the appointment of the new Editor-in-Chief of the Journal of Clinical Oncology who tells us (during his visit to China) he is committed to continue the policy of global co-operation in clinical cancer research publishing. He is: Thomas Eldridge Stinchcombe MD, FASCO, Medical Oncologist and Member of the Thoracic Oncology Program at Duke Cancer Institute in Durham, North Carolina, in the USA. At the 2026 Annual Meeting of the Chinese Society of Clinical Oncology he talked about his plans with our reporter, Peter Goodwin.
Fang Wu MD PhD; CSCO 2026: Could Emotional Distress Medicines Prolong Survival in Patients with Small Cell Lung Cancer?
2026/10/01
JINAN, China—Provocative evidence is emerging that emotional distress can adversely affect outcomes among patients with lung cancer. Data from a study of the role of hormones in affecting lung cancer outcomes were reported at the 2026 Annual Meeting of the Chinese Society of Clinical Oncology in an oral communication entitled: Clinical Impact of Baseline Hormones on Outcomes of First Line Immunotherapy in Extensive Stage Small-Cell Lung Cancer. Peter Goodwin discussed the findings with first author Fang Wu MD PhD, Deputy Director, Chief Physician, Professor and Doctoral Supervisor in the Department of Oncology at the Second Xiangya Hospital Cancer Center in Central South University, Changsha, China.
Luciano J. Costa MD PhD; IMS 2026: Teclistamab plus Daratumumab in Patients with Relapsed or Refractory Multiple Myeloma brings “Dramatic Reduction” of Progression Risk, Without Increased Risk of Death: MajesTEC-3 Phase Three Study Findings
2026/09/30
GLASGOW, Scotland—A combination of the bi-specific T-cell engager antibody teclistamab (that targets both B-cell maturation antigen and CD-3) paired with the anti-CD-38 monoclonal antibody daratumumab markedly extended relapse-free survival, and improved overall survival among patients with relapsed or refractory multiple myeloma in comparison with standard of care triplet therapy. This was in the international multi-center phase three MajesTEC-3 study reported at the 2026 Annual Meeting of the International Myeloma Society. Sarah Maxwell caught up with lead author Luciano Costa MD PhD, Professor of Medicine and Director of the Multiple Myeloma Research and Treatment Program at the University of Alabama, in Birmingham, USA.
Feng Wang PhD MD; CSCO 2026: Progress and Prospects of New Drug Research for Colorectal Cancer: The View from China
2026/09/29
JINAN, China—The 2026 Annual Meeting of the Chinese Society of Clinical Oncology, with more than 40 000 cancer clinicians attending, heard evidence from clinical trial findings and new science bringing great hope for the treatment of colorectal cancer. The era of targeted precision medicine for colorectal cancer had truly arrived, delegates heard, with a long list of potential targets identified by genetic testing, and an impressive range of promising agents to match them to treat cancer in new and more effective ways. In an abstract entitled: “Progress and Prospects of New Drug Research for Colorectal Cancer”, the latest state of the art in colorectal cancer research was assessed by Feng Wang PhD MD, Director of Medical Oncology at Sun Yat-sen University Cancer Center, in Guangzhou, China. Afterwards, she talked with our reporter, Peter Goodwin:
Philippe Moreau MD; IMS 2026: International Myeloma Society President Discusses Key Themes, Future Directions and Challenges in Newly Diagnosed Multiple Myeloma
2026/09/28
GLASGOW, Scotland—Philippe Moreau MD, President of the International Myeloma Society, talks with Audio Journal of Oncology correspondent Sarah Maxwell about the key themes, future directions and challenges in newly diagnosed multiple myeloma under discussion at the 2026 Annual Meeting, including new drugs and the prospects for cure.

Podcast reviews

Read Audio Journal of Oncology Podcast podcast reviews


0 out of 5
0 reviews

Podcast sponsorship advertising

Start advertising on Audio Journal of Oncology Podcast relevant audience podcasts


What do you want to promote?